695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

• Rakesh Kumar,
• Keunchil Park,
• Frances A Shepherd,
• John V Heymach,
• Quincy Chu,
• Sylvia Hartl,
• J Carl Barrett,
• Sonia Iyer,
• Parneet Cheema,
• Marianna Koczywas,
• Maximilian Hochmair,
• Giuseppe Galletti,
• Mark Gustavson,
• Brent Evans,
• Jan Cosaert

Affiliations

Rakesh Kumar

2AstraZeneca, Gaithersburg, MD, USA

Keunchil Park

Aff1 0000 0001 2181 989Xgrid.264381.aDivision of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine 81 Irwon-ro, Gangnam-Gu 60351 Seoul Republic of Korea

Frances A Shepherd

5Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada

John V Heymach

Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Quincy Chu

Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada

Sylvia Hartl

Ludwig Boltzmann Institute of COPD and Respiratory Care, Department of Respiratory and Critical Care, Otto Wagner Hospital, Vienna, Austria

J Carl Barrett

2AstraZeneca, Waltham, MA, USA

Sonia Iyer

2AstraZeneca, Waltham, MA, USA

Parneet Cheema

1University of Toronto, Toronto, ON, Canada

Marianna Koczywas

3City of Hope National Medical Center, Duarte, CA, USA

Maximilian Hochmair

4Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria

Giuseppe Galletti

7Weill Cornell Medicine, New York, NY, USA

Mark Gustavson

8AstraZeneca, Gaithersburg, MD, USA

Brent Evans

8AstraZeneca, Gaithersburg, MD, USA

Jan Cosaert

11AstraZeneca, Cambridge, UK